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Abstract
Background: Inflammation of adipose tissue (AT) has been recently accepted as a first step towards obesity-
mediated insulin resistance. We could previously show that mice fed with high fat diet (HFD) develop systemic
insulin resistance (IR) and glucose intolerance (GI) associated with CD4-positive T-lymphocyte infiltration into
visceral AT. These T-lymphocytes, when enriched in AT, participate in the development of fat tissue inflammation
and subsequent recruitment of proinflammatory macrophages. The aim of this work was to elucidate the action of
the insulin sensitizing PPARgamma on T-lymphocyte infiltration during development of IR, and comparison of the
PPARgamma-mediated anti-inflammatory effects of rosiglitazone and telmisartan in diet-induced obesity model
(DIO-model) in mice.
Methods: In order to investigate the molecular mechanisms underlying early development of systemic insulin
resistance and glucose intolerance male C57BL/6J mice were fed with high fat diet (HFD) for 10-weeks in parallel
to the pharmacological intervention with rosiglitazone, telmisartan, or vehicle.
Results: Both rosiglitazone and telmisartan were able to reduce T-lymphocyte infiltration into AT analyzed by
quantitative analysis of the T-cell marker CD3gamma and the chemokine SDF1alpha. Subsequently, both
PPARgamma agonists were able to attenuate macrophage infiltration into AT, measured by the reduction of MCP1
and F4/80 expression. In parallel to the reduction of AT-inflammation, ligand-activated PPARgamma improved diet-
induced IR and GI.
Conclusion: Together the present study demonstrates a close connection between PPARgamma-mediated anti-
inflammation in AT and systemic improvement of glucose metabolism identifying T-lymphocytes as one cellular
mediator of PPARgamma´s action.
Background
The prevalence of metabolic diseases such as obesity,
type 2 diabetes and obesity-associated hypertension is
increasing gradually [1]. Given that IR was shown to
correlate with reduction of insulin-mediated glucose
uptake in skeletal muscle and adipose tissue, IR was
recently recognized as a key etiological factor of those
metabolic disorders [2]. The molecular mechanisms
underlying the development of obesity-directed IR are
not well understood. Several lines of evidence support
the thesis, that the first step towards the development of
autonomous insulin resistance in adipose tissue, as well
as in the liver, is inflammation [3-5].
Pro-inflammatory cytokines produced by adipocytes in
fat tissue such as TNFalpha and IL-6 accelerate inflam-
matory responses of the surrounding tissue, and recruit
pro-inflammatory cells. Recently we were able to show
that the first inflammatory cells recruited to the adipose
tissue during development of obesity-induced IR are
CD4-positive T-lymphocytes [6]. The recruitment of T-
lymphocytes into fat tissue is likely mediated through
resident adipocytes expressing stromal cell-derived
* Correspondence: ulrich.kintscher@charite.de
1Center for Cardiovascular Research (CCR), Institute of Pharmacology Charité
- Universitätsmedizin Berlin, Germany
Full list of author information is available at the end of the article
Foryst-Ludwig et al. Cardiovascular Diabetology 2010, 9:64
http://www.cardiab.com/content/9/1/64
CARDIO
VASCULAR 
DIABETOLOGY
© 2010 Foryst-Ludwig et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.factor-1 alpha (SDF-1alpha), a known attractant mole-
cule for T-cells. In parallel, adipocytes produce mono-
cyte chemoatractant protein-1 (MCP-1) for subsequent
attraction of macrophages. Then, CD4-positive T-lym-
phocytes are able to induce pro-inflammatory responses
in macrophages by the release of interferon gamma
(IFNgamma) [6,7]. It is well known that macrophages
which are recruited during the development of the obe-
sity-related IR to fat tissue belong to the “pro-inflamma-
tory” M1-phenotype [3,8]. Several independent research
groups have demonstrated, that M1 macrophages are
highly activated, sensitive to lipopolysaccharide (LPS)
and free fatty acids (FFA), express F4/80, CD11b and
CD11c markers as well as toll like receptors (TLR) 2
and 4, and produce a wide range of pro-inflammatory
cytokines, such as TNFalpha and IL-6. This is in con-
trast to resident anti-inflammatory M2 macrophages,
with a low sensitivity to LPS and FFA, lack of CD11c
marker, and production of anti-inflammatory cytokines
such as IL-4 and IL-10 [3,8,9]. Recently Stienstra and
colleagues [10] reported the M2- to M1-transition of
resident adipose tissue specific macrophages (ATM) in
rodents fed with HFD. Additionally, the authors showed
that the transition could be inverted in HFD-fed mice
treated with the PPARgamma agonist rosiglitazone.
PPARgamma belongs to the nuclear hormone receptor
family of transcription factors, which are activated upon
binding of specific ligands or agonists. PPARgamma is a
key regulator of glucose and lipid metabolism by control-
ling energy homeostasis in adipose tissue, liver and skele-
tal muscle [11]. Glitazones or Thiazolidinediones (TZDs),
such as pioglitazone and rosiglitazone, are potent syn-
thetic PPARgamma agonists used in clinic to treat type 2
diabetes [12]. The activation of PPARgamma leads to
improvement of systemic IR/glucose tolerance and the
metabolic function of adipose tissue, liver and skeletal
muscle. Recently we could demonstrate that a subgroup
of angiotensin type 1 receptor (AT1R) blockers (ARBs)
such as telmisartan act as a partial PPARgamma agonists,
and show - similar to full agonists-beneficial metabolic
effects in mouse model of HFD-induced IR [13].
The aim of the present study was to elucidate the role
of ligand-activated PPARgamma activation on T-lym-
phocyte-derived adipose tissue inflammation. Our data
indicate that PPARgamma plays a central role in the
development of IR, acting as an anti-inflammatory factor
on T-lymphocyte activation and infiltration into fat tis-
sue, and by this mean contributing to the attenuation of
the systemic development of IR.
Methods
1. Mice Model
Male C57BL/6J mice, 4-5 weeks of age, were purchased
from Harlan Winkelmann (Borchen, Germany). All mice
were housed in a temperature controlled (25°C) facility
with a 12 h light/dark cycle. Mice were randomised to
either a vehicle-treated (0.5% Tween80/H2O), rosiglita-
zone-treated (10 mg/kg/d), or telmisartan-treated (3 mg/
kg/day) group (all applied by oral gavage) and fed with a
high-fat diet (HFD (60% kcal from fat). Age-match low
fat diet (LFD (10% kcal from fat)-fed mice served as
controls [13] for 5- and 10-weeks respectively. To
exclude differences induced by food intake, all HFD-fed
mice were pair-fed. After 5- and 10-weeks on HFD ani-
mals were metabolically phenotyped including an intra-
peritoneal glucose tolerance test (ipGTT) using a dose
of 1 g/kg body weight glucose, and an insulin tolerance
test (ITT) by injecting 0.25 U/kg body weight insulin
(ActrapidHM, Novo Nordisk) intraperitoneally. Tail vein
blood was used for glucose quantification during ipGTT
and ITT using a Glucometer (Precision Xtra, Abbott).
Afterwards, animals were sacrificed and organs were dis-
sected. All animal procedures were in accordance with
institutional guidelines and were approved.
2. Immunohistological staining
For immunohistological studies, gonadal adipose tissue
was fixed in 4% formalin, embedded in paraffin and
stained with the corresponding antibodies. The follow-
ing antibodies were used: lymphocytes were identified
by staining with an anti-mouse CD3gamma antibody
(Serotec, MCA 1477) and macrophages were detected
using Macrophage Marker (RM0029-11H3), a monoclo-
nal antibody raised against isolated macrophages of
mouse origin, (Santa Cruz, SC-101447). Control staining
was performed using type and isomatched IgG
antibodies.
3. Quantitative real-time PCR
Quantitative real-time PCR was performed as previously
described [14]. Briefly, total RNA was isolated from gona-
dal adipose tissue using Trizol (Invitrogen) according to
the manufacturer’s instructions. The quantitative PCR
reactions were carried out in the presence of a fluores-
cent dye (Sybrgreen, BioRad). Relative abundance of
mRNA was calculated after normalisation to 18s riboso-
mal RNA. The expression of MCP1, F4/80, SDF-1alpha
and CD3gamma were measured using assay on demand
(Mm00441242-m1; Mm00802529-m1; Mm00445552-m1
and MM00438095 respectively, from Life Technologies).
Results
1. Early stages of systemic insulin resistance and glucose
intolerance are attenuated by ligand-mediated
PPARgamma activation
In order to investigate the molecular mechanisms
underlying early development of systemic insulin resis-
tance and glucose intolerance male C57BL/6J mice were
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the pharmacological intervention with rosiglitazone (10
mg/kg/d), telmisartan (3 mg/kg/d), or vehicle. Mice fed
with low fat diet (LFD) were used as control (data not
shown). Total body weight of the HFD-fed mice after
10-weeks of intervention was significantly increased in
vehicle treated animals, when compared to LFD-fed lit-
termates (data not shown). When treated with telmisar-
tan, a partial PPARgamma agonist, HFD-fed mice
showed a significant reduction of body weight (BW),
apparent as soon as after 5-weeks of treatment (Table
1). Significant reduction of BW was also observed in
rosiglitazone-treated HFD mice after 10-weeks of treat-
ment, when compared to the vehicle treated group,
which could be explain, at least in part, by the pair feed-
ing protocol (Table 1). Food intake among vehicle-, tel-
misartan- and rosiglitazone-treated HFD-fed mice was
similar (Table 2).
Increased body weight gain observed in vehicle-treated
mice after 5- and 10-weeks of HFD feeding was accom-
panied with the development of IR and GI, shown in
the ipGTT and ITT tests (Figure 1 and 2). Pharmacolo-
gical intervention with both rosiglitazone and telmisar-
tan led to a significant improvement of GI after 5- and
10-weeks of treatment in our model (Figure 1A and 1B).
In accordance, relative insulin sensitivity was signifi-
cantly increased in mice treated with PPARgamma
ligands (Figure 2A and 1B).
These experiments suggest that activation of PPAR-
gamma by the full agonist rosiglitazone as well as the
partial agonist telmisartan results in an improvement of
HFD-induced metabolic phenotypes.
2. Ligand-mediated PPARgamma activation inhibits
T-lymphocytes infiltration into in adipose tissue during
HFD-induced insulin resistance
We and others have recently demonstrated that early IR
correlates with the infiltration of T-lymphocytes into
adipose tissue [6,15]. To follow this idea we examined
the expression of T-lymphocyte marker CD3 in abdom-
inal fat tissue of HFD-fed mice treated with PPAR-
gamma agonists. Expression of T-lymphocyte specific
chemoattractants such as SDF-1alpha and T-lymphocyte
marker CD3gamma were strongly reduced after 5-and
10-weeks of pharmacological interventions (Figure 3A
and 3B). The mRNA expression data were verified by
immunohistological analysis of adipose tissue sections
from treated- and untreated-obese mice, as shown in
Figure 3C. T-lymphocytes could be detected after
5- weeks HFD in vehicle-treated animals. Both PPAR-
gamma ligands completely diminished T-cell staining
after 5- and 10-weeks of HFD, indicating that PPAR-
gamma activation prevents T-cell recruitment into adi-
pose tissue during HFD-feeding.
These results indicate a novel putative mechanism of
anti-inflammatory action of PPARgamma during early
insulin resistance.
3. Accumulation of macrophages in adipose tissue is
inhibited by PPARgamma activation
Accumulation of macrophages in adipose tissue is a cen-
tral pathogenetic process during the development of
diet-induced IR. In consonance, after 10-weeks of HFD,
we were able to detect an increased expression of the
macrophage marker F4/80, as well as MCP-1, in adipose
tissue from vehicle-treated mice (Figure 4A and 3B).
These data was accompanied by a positive immunohis-
tological staining for macrophages (RM0029-11H3) in
adipose tissue sections of vehicle-treated HFD-fed mice
(Figure 4C). The expression of both F4/80 and MCP-1
was strongly reduced in adipose tissue from rosiglita-
zone- and telmisartan-treated- HFD-fed mice (Figure
4A). We could also confirm our findings by immunohis-
tological analysis with RM0029-11H3-specific staining
(Figure 4B). Interestingly, macrophage staining and mar-
ker mRNA (F4/80, MCP-1) expression was absent in
5- weeks vehicle-treated HFD animals corroborating
that macrophages infiltration is likely a later event in
diet-induced IR.
Taken together our data illustrate a new anti-inflam-
matory action of PPARgamma regarding anti-inflamma-
tion, which may have an impact on the development
and progression of IR. Our experiments demonstrate
Table 1 Body weight development after 5 and 10 weeks of HFD
BW (g) 5 Weeks of HFD 10 Weeks of HFD
Vehicle 24.8 ± 2.3 30.5 ± 2.5
Rosi 24.7 ± 1.4 p < 0.05 vs. Telmi 27.8 ± 1.0 p < 0.05 vs. Veh
p < 0.05 vs. Telmi
Telmi 23.6 ± 1.5 p < 0.05 vs. Veh 24.7 ± 1.2 p < 0.05 vs. Veh
Table 2 Food intake after 5 and 10 weeks of HFD (pair-
feeding)
Food Intake
(g/day/mouse)
5 Weeks of HFD 10 Weeks of HFD
Vehicle 1.2 ± 0.1 1.1 ± 0.2
Rosi 1.1 ± 0.6 ns 1.0 ± 0.1 ns
Telmi 1.1 ± 0.2 ns 1.0 ± 0.1 ns
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reduced by the intervention with PPARgamma agonists.
Discussion
The present study demonstrates that activation of
PPARgamma reduces HFD-induced T-lymphocyte infil-
tration into adipose tissue. Both PPARgamma agonists,
rosiglitazone and telmisartan, were able to reduce diet-
induced T-lymphocyte accumulation in fat tissue. Subse-
quently, PPARgamma activation was linked to reduced
macrophage infiltration into adipose tissue of HFD-fed
mice. Anti-inflammatory actions of PPARgamma in adi-
pose tissue were associated with an improved metabolic
phenotype of mice treated with PPARgamma agonists
for 5- and 10-weeks parallel to the HFD-intervention.
T-lymphocytes were recently shown to initiate the
inflammatory response associated with obesity-related
IR. Our data demonstrate for the first time a new anti-
Figure 1 PPARgamma activation improves systemic insulin
sensitivity of HFD-fed mice. A) Glucose tolerance test (GTT) of
LFD-fed, HFD-fed and vehicle-, rosiglitazone-, or telmisartan-treated
mice after 10-weeks of intervention, as indicated and described in
Methods, n = 10; *p < 0.05 rosiglitazone-treated mice vs. vehicle-
treated animals,°p < 0.05 telmisartan-treated mice vs. vehicle-treated
animals, #p < 0.05 LFD-fed vs. HFD-fed, vehicle-treated mice. B)
Glucose tolerance test (GTT) of HFD-fed, vehicle-, rosiglitazone-, or
telmisartan-treated mice after 5- and 10-weeks of intervention, as
indicated. From each group area under the curve (AUC) was
calculated, as described in Methods, n = 10;°p < 0.05 rosiglitazone-
treated mice vs. vehicle-treated animals; *p < 0.05 telmisartan-
treated mice vs. vehicle-treated animals.
Figure 2 PPARgamma activation improves systemic and
glucose tolerance DIO mice model. A) Insulin tolerance test (ITT)
of LFD-fed, HFD-fed and vehicle-, rosiglitazone-, or telmisartan-
treated mice after 10-weeks of intervention, as indicated and
described in Methods, n = 10; *p < 0.05 rosiglitazone-treated mice
vs. vehicle-treated animals,°p < 0.05 telmisartan-treated mice vs.
vehicle-treated animals, #p < 0.05 LFD-fed vs. HFD-fed, vehicle-
treated mice. B) Insulin tolerance test (ITT) of HFD-fed, vehicle-,
rosiglitazone-, or telmisartan-treated mice after 5- and 10-weeks of
intervention, as indicated. From each group area under the curve
(AUC) was calculated, as described in Methods, n = 10;°p < 0.05
rosiglitazone-treated mice vs. vehicle-treated animals; *p < 0.05
telmisartan-treated mice vs. vehicle-treated animals.
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Analysis of SDF-1alpha mRNA expression levels and B) analysis of CD3gamma in abdominal fat from HFD-fed and vehicle-, rosiglitazone-, or
telmisartan-treated mice after 5- and 10-weeks of intervention; °°p < 0.01 rosiglitazone-treated mice vs. vehicle-treated animals; °p < 0.05
rosiglitazone-treated mice vs. vehicle-treated animals, **p < 0.01 telmisartan-treated mice vs. vehicle-treated animals; *p < 0.05 telmisartan-
treated mice vs. vehicle-treated animals. C) Immunohistological analysis of the gonadal fat tissue sections isolated from HFD-fed and vehicle-,
rosiglitazone-, or telmisartan-treated mice after 5- and 10-weeks of intervention; stained with CD3-specific antibody, as described in Methods.
Positive cells are indicated by an arrow. For control staining spleen sections were used. For the negative control the same sections of gonadal
adipose tissue isolated from HFD-fed mice were stained with unspecific IgG-antibodies, as indicated.
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levels and B) analysis of F4/80 in abdominal fat from HFD-fed and vehicle-, rosiglitazone-, or telmisartan-treated mice after 10-weeks of
intervention; °°p < 0.01 rosiglitazone-treated mice vs. vehicle-treated animals; °p < 0.05 rosiglitazone-treated mice vs. vehicle-treated animals,
**p < 0.01 telmisartan-treated mice vs. vehicle-treated animals. C) Immunohistological analysis of the gonadal fat tissue sections isolated from
HFD-fed mice treated with vehicle, rosiglitazone, or telmisartan after 10-weeks of intervention; stained with monoclonal antibody detecting
mouse macrophage marker (RM0029-11H3-specific antibody), as described in Methods. Positive cells are indicated by an arrow. As positive
control spleen sections were used. For the negative control the same sections of gonadal adipose tissue isolated from HFD-fed mice were with
unspecific IgG-antibodies, as indicated.
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T-cells, which may contribute to the beneficial meta-
bolic actions of PPARgamma ligands.
The ARB telmisartan has been shown to improve
metabolic outcome of DIO-mice [13]. Although the
molecular mechanism of telmisartan´s action is not fully
understood, its beneficial metabolic properties are linked
to the ability to activate PPARgamma as a partial ago-
nist, similarly to potent anti-diabetic drugs such as
TZDs [13,16]. Telmisartan has also been demonstrated
to modulate hepatic mitochondrial fatty acid oxidation
due to the activation of hepatic PPARalpha [17]. Along
that line, a recently published study from Rong. X and
colleagues on AT1R-deficient mice indicates for the
first time that beneficial effects of telmisartan on diet-
induced obesity, insulin resistance and hepatic
triglyceride accumulation in mice appear to be AT1-R
independent [18].
Recent work published by Hernandez-Trujillo and col-
leagues [19] demonstrated that the administration of
rosiglitazone or losartan tom i c ef e dah i g h - f a t ,h i g h -
cholesterol diet increases PPARgamma activity in both
cases. Interestingly, treatment with rosiglitazone showed
anti-atherogenic properties, such as a significant reduc-
tion of eNOS and CD36 expression, when compared to
littermates treated with losartan. Furthermore, rosiglita-
zone has been shown to improve endothelial dysfunc-
tion in femoral arteries of Zucker diabetic fatty rats,
mainly due to the regulation of eNOS expression and
enhancement of endothelium-dependent vasorelaxation.
Rosiglitazone treatment did not affect the mechanical
properties of the artery as well as an expression of
alpha-adrenoceptor (alpha-AR), MMP9 and elastase in
this model [20].
Importantly, treatment with both rosiglitazone and tel-
misartan led to the reduction of BW after 10 weeks of
HFD, when compared to vehicle-treated littermates.
Pair-feeding protocols reduced but not fully eliminated
the differences in BW observed in HFD-fed mice treated
with rosiglitazone and telmisartan. The BW difference
can potentially have an impact on the anti-inflammatory
and anti-diabetic properties of those two PPARgamma
agonists.
In previous studies we characterized the role of T-
lymphocytes in adipose tissue inflammation [6]. Lym-
phocyte infiltration occurs during the early phases of IR
development in HFD-induced obesity and precedes adi-
pose tissue macrophage accumulation. Furthermore, it
was demonstrated by us and the others, that activation
of PPARgamma by TZDs or telmisartan reduces inflam-
matory T-cell activity, C-peptide-induced T-cell chemo-
taxis, and SDF-1- directed T-cell migration in vitro
[21-24], indicating an important function of PPAR-
gamma in T-cells. Along this line, our present study
shows that ligand-mediated PPARgamma activation pre-
vents T-cell infiltration into adipose tissue which was
associated with an improvement of diet-induced IR.
In their recent study Winer and colleagues identified,
similar to our data, a residential population of T4-lym-
phocytes that controlled insulin resistance in visceral
adipose tissue of HFD-fed mice. In elegant transplanta-
tion experiments with CD4
+ T-lymphocyte transfer into
lymphocyte-free Rag1-null- and HFD-fed mice the
authors showed reversed weight gain and improved IR
of these mice in comparison to control littermates pre-
dominantly mediated through anti-inflammatory TH2
cells [15]. In addition, a distinct set of the CD4
+ and
Foxp3
+- T-cells (T-regs) were recently identified in adi-
pose tissue from lean rodents. These cells have been
also suggested to play a regulatory role of the metabolic
phenotype modulating an anti-inflammatory response in
adipose tissue [25]. Accordingly, the population of T-reg
cells was dramatically reduced in adipose tissue of mice
with obesity-related IR confirming a beneficial function
of this T-cell population. It appears that a pro- and
anti-inflammatory subset of CD4
+ T-lymphocytes does
exist in adipose tissue, and the balance betweens these
populations likely determines the phenotype. In our
s t u d yw ed i dn o ti n v e s t i g a t eC D 4
+ T-lymphocyte sub-
sets; however, as previously described in other studies
using the HFD model, pro-inflammatory TH1 cells are
the predominant subset during weight gain. Therefore it
is likely that PPARgamma ligands mainly target TH1
cells in our model to mediate their anti-inflammatory
action.
In addition to the reduction of T-lymphocyte accu-
mulation by PPARgamma ligands we demonstrate that
the amount of macrophages is reduced in groups trea-
ted with rosiglitazone or telmisartan. Accordingly to
the characterization of CD4
+ T-lymphocyte subsets in
adipose tissue, distinct subpopulations (pro-inflamma-
tory M1 and anti-inflammatory M2) of macrophages
have been identified in adipose tissue [3,10]. PPAR-
gamma has been recently demonstrated to promote
infiltration of M2 (anti-inflammatory) macrophages
into adipose tissue in DIO model in mice [10]. In this
work mice were fed with HFD over 20-weeks, followed
by 1-week treatment with rosiglitazone (0.01% w/w)
the authors reported a striking up-regulation of the
MCP-1 expression in the adipose tissue of rosiglita-
zone-treated mice, which is in contrast to our data, as
well as to the results in human and murine adipose tis-
s u ep u b l i s h e db yo t h e r s[ 5 , 26]. This discrepancy
between our data and results published by Stienstra
and colleagues could be explained, at least in part, by
the different DIO model used in the study. Stienstra
and colleagues investigated chronic fat tissue inflam-
mation followed by a short pharmacological
Foryst-Ludwig et al. Cardiovascular Diabetology 2010, 9:64
http://www.cardiab.com/content/9/1/64
Page 7 of 9intervention with rosiglitazone. We were interested in
the early stages of IR development, and mice used in
our work were set on HFD parallel to the rosiglita-
zone/telmisartan intervention for over 10-weeks. In
our mice model we could observe a clear reduction of
adipose tissue MCP-1 by PPARgamma agonists, which
is in agreement with previously published data [5].
Stienstra and collaborators observed also enhanced
infiltration of M2 macrophages after rosiglitazone
intervention, when compared to vehicle-treated ani-
mals. This is in agreement with data published by Bas-
saganya-Riera and others [9], showing that deficiency
of PPARgamma in immune cells results in significant
upregulation of the M1 markers and repression of M2
markers characteristic for macrophages in white adi-
pose tissue of mice with HFD-induced obesity. Lack of
PPARgamma led to the dominance of M1 differentia-
tion in this model. Following this line, reduction of
MCP-1 and macrophage markers by PPARgamma
ligands in our study likely reflect the diminution of
pro-inflammatory M1-macrophages during the early
development of obesity/IR. Enhancement of M2-
macrophage responses by PPARgamma activation
might be a feature of late phase during HFD feeding.
Although our study clearly indicate that macrophage
infiltration and the progression of fat tissue inflamma-
tion and IR could be specifically reduced by the inter-
vention with PPARgamma agonists, one has to take into
account that conclusion derived form animal studies in
general cannot be automatically extrapolated to human
or to clinical studies, as treatment with rosiglitazone
was recently linked with increased cardiovascular risk
[27].
Conclusion
In summary, we have shown for the first time the inhi-
bitory properties of PPARgamma activation on T-lym-
phocyte-derived adipose tissue inflammation. Our data
indicate a novel mechanism of PPARgamma function in
the development of IR, acting as a potent anti-inflam-
matory factor on T-lymphocyte activation and infiltra-
tion into fat tissue, and by this mean contributing to the
attenuation of the systemic development of IR.
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